Boundless Bio (BOLD) Income from Continuing Operations (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Income from Continuing Operations of 81631000.0 for Q1 2026, down 414.83% year-over-year from 25928827.42 in Q1 2025, and down 455.88% quarter-over-quarter from 14685000.0 in Q4 2025.
Boundless Bio (BOLD) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Income from Continuing Operations for 4 consecutive years, with 81631000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 414.83% year-over-year to 81631000.0; the TTM figure through Mar 2026 stood at 206311000.0 (down 196.45% YoY), while the FY2025 annual figure was 60795000.0, up 10.56% from the prior year.
- Income from Continuing Operations retreated to 81631000.0 in Q1 2026 per BOLD's latest filing, from 14685000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12392000.0 in Q1 2023 and bottomed at 85429000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 29116076.92 across 4 years, with a median of 16641000.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 68.49% — and 2026, when it slumped 414.83%.
- Boundless Bio's Income from Continuing Operations stood at 12876000.0 in 2023, then plunged by 30.96% to 16863000.0 in 2024, then grew by 12.92% to 14685000.0 in 2025, then slumped by 455.88% to 81631000.0 in 2026.
- Business Quant data shows BOLD's Income from Continuing Operations at 81631000.0 in Q1 2026, 14685000.0 in Q4 2025, and 85429000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Boundless Bio | 64.88 Mn | 64.88 Mn | - | -23.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.43 Mn |
| Mar 31, 2026 | -81.63 Mn |
| Dec 31, 2025 | -14.69 Mn |
| Sep 30, 2025 | -85.43 Mn |
| Jun 30, 2025 | -24.57 Mn |
| Mar 31, 2025 | -15.86 Mn |
| Dec 31, 2024 | -16.86 Mn |
| Sep 30, 2024 | -16.64 Mn |
| Jun 30, 2024 | -20.23 Mn |
| Mar 31, 2024 | -50.32 Mn |
| Dec 31, 2023 | -12.88 Mn |
| Sep 30, 2023 | -13.91 Mn |
| Jun 30, 2023 | -13.11 Mn |
| Mar 31, 2023 | -12.39 Mn |